Research in Dr. Cantor’s lab is focused on identifying what is wrong with Fanconi anemia patient cells. Fanconi anemia patient cells are very sensitive to agents that interfere with DNA replication. Even in the absence of exogenous genotoxic stress, Fanconi anemia cells have abnormally elevated DNA damage response (DDR). In patients, this constitutively active DDR is most prominent in rapidly dividing tissue and correlates with bone marrow failure. Understanding the underlying cause of the overactive DDR in Fanconi anemia cells could provide clues for therapeutic intervention, to mitigate bone marrow failure or prevent malignancy in Fanconi anemia patients.
At the Li Weibo Institute for Rare Diseases Research, our researchers and clinicians are dedicated to finding new treatment options for patients. Our clinical trials program is another way we continue to advance treatments and make new discoveries. If you or someone you know may be interested in a clinical trial, please subscribe for updates and you will be notified when we open up a new trial.
There are more than 7,000 diseases defined as “rare” by the National Institutes of Health, generally those that impact fewer than 200,000 people. Please select disease or condition from the list below for more information about the latest in research, clinical trials and therapy strategies.
Li Weibo Institute for Rare Diseases Research is committed to advancing the research for all the diseases our investigators study. We are continuously investing in the latest technologies, therapeutics, and facilities in order to provide our researchers with the most equipped infrastructure available.
